Trials / Terminated
TerminatedNCT00571142
Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema
Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Asociación para Evitar la Ceguera en México · Academic / Other
- Sex
- All
- Age
- 25 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Bevacizumab + Pars plana vitrectomy | 2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional. |
| PROCEDURE | Bevacizumab + pars plana vitrectomy | 2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2007-11-01
- Completion
- 2008-02-01
- First posted
- 2007-12-11
- Last updated
- 2024-05-31
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT00571142. Inclusion in this directory is not an endorsement.